Department of Psychiatry, Shakomae Kokorono Clinic, Tokyo, Japan.
Department of Psychiatry, Suzuki Clinic, Tokyo, Japan.
Brain Behav. 2021 May;11(5):e02109. doi: 10.1002/brb3.2109. Epub 2021 Mar 13.
The current study sought to compare the treatment continuation rates of asenapine and brexpiprazole while specifically investigating the factors influencing this index and the clinical efficacy of brexpiprazole.
Retrospective study on patients with schizophrenia who were prescribed either asenapine (n = 73) or brexpiprazole (n = 136), as part of their routine medical care.
The treatment continuation rates for asenapine and brexpiprazole were 19.0% and 38.6% at 52 weeks, with that of brexpiprazole found to be significantly higher than that of asenapine (p = .002). Moreover, age was found to be a significant factor affecting the treatment continuation rate for brexpiprazole (p = .03). Additionally, patients with a longer continuation duration had significantly lower Clinical Global Impression-Severity of Illness (CGI-S) scale scores compared to those who discontinued early (p = .04). The continuation rate was also significantly higher for those who began using the drug as outpatients compared to those first administered the drug as inpatients (p = .04). Furthermore, disease duration, CGI-S scale, and continuation duration significantly affected the clinical efficacy of brexipiprazole (p < .05 for all).
The continuation rate for brexpiprazole increases as the age of the patient increases, as disease severity decreases, and if the patient first uses the drug as an outpatient. Shorter disease duration and longer drug administration may lead to improved clinical efficacy. These results suggest that brexpiprazole is an effective treatment option for maintenance therapy of schizophrenia.
本研究旨在比较阿塞那平与布瑞哌唑的治疗延续率，同时特别考察影响该指标的因素及布瑞哌唑的临床疗效。
回顾性研究了在常规医疗中分别处方阿塞那平（n=73）和布瑞哌唑（n=136）治疗的精神分裂症患者。
阿塞那平和布瑞哌唑在 52 周时的治疗延续率分别为 19.0%和 38.6%，布瑞哌唑的治疗延续率明显高于阿塞那平（p=0.002）。此外，年龄是影响布瑞哌唑治疗延续率的显著因素（p=0.03）。另外，与早期停药的患者相比，持续时间更长的患者的临床总体印象-严重程度量表（CGI-S）评分显著降低（p=0.04）。与首次住院用药的患者相比，作为门诊患者开始使用该药的患者的延续率也显著更高（p=0.04）。此外，疾病持续时间、CGI-S 量表和延续时间均显著影响布瑞哌唑的临床疗效（p<0.05）。
随着患者年龄的增加、疾病严重程度的降低以及患者首次作为门诊患者使用药物，布瑞哌唑的延续率会增加。较短的疾病持续时间和较长的药物管理时间可能会提高临床疗效。这些结果表明，布瑞哌唑是精神分裂症维持治疗的有效治疗选择。
